Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a pre-existing royalty interest in Nuvalent’s neladalkib and zidesamtinib from an undisclosed third party for up to $315 million.
Over the past year, we’ve reported on countless problems with Microsoft’s Outlook apps, and they’re still coming. This time, it’s about difficulties opening the new Outlook app in Windows, something ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback